LT2544536T - Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas - Google Patents

Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas

Info

Publication number
LT2544536T
LT2544536T LTEP11753975.9T LT11753975T LT2544536T LT 2544536 T LT2544536 T LT 2544536T LT 11753975 T LT11753975 T LT 11753975T LT 2544536 T LT2544536 T LT 2544536T
Authority
LT
Lithuania
Prior art keywords
quetiapine
making
same
fatty acid
acid conjugates
Prior art date
Application number
LTEP11753975.9T
Other languages
English (en)
Inventor
Travis Mickle
Sven Guenther
Sanjib Bera
Original Assignee
Kempharm, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm, Inc. filed Critical Kempharm, Inc.
Publication of LT2544536T publication Critical patent/LT2544536T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP11753975.9T 2010-03-11 2011-03-09 Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas LT2544536T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31297710P 2010-03-11 2010-03-11
PCT/US2011/027658 WO2011112657A1 (en) 2010-03-11 2011-03-09 Fatty acid conjugates of quetiapine, process for making and using the same

Publications (1)

Publication Number Publication Date
LT2544536T true LT2544536T (lt) 2019-02-25

Family

ID=44560214

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11753975.9T LT2544536T (lt) 2010-03-11 2011-03-09 Kvetiapino riebalų rūgšties konjugatai, jų gamybos būdas ir panaudojimas

Country Status (15)

Country Link
US (7) US20110223207A1 (lt)
EP (2) EP2544536B1 (lt)
CY (1) CY1121106T1 (lt)
DK (1) DK2544536T3 (lt)
ES (1) ES2705233T3 (lt)
HR (1) HRP20190057T1 (lt)
HU (1) HUE042945T2 (lt)
LT (1) LT2544536T (lt)
PL (1) PL2544536T3 (lt)
PT (1) PT2544536T (lt)
RS (1) RS58335B1 (lt)
SI (1) SI2544536T1 (lt)
SM (1) SMT201900079T1 (lt)
TR (1) TR201900067T4 (lt)
WO (1) WO2011112657A1 (lt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148517A1 (en) * 2009-06-26 2010-12-29 Asteia Technology Inc. Non-braided, textile-reinforced hollow fiber membrane
CA2785846C (en) 2009-12-31 2015-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
RU2605251C2 (ru) 2010-09-15 2016-12-20 БиЭл Текнолоджиз, Инк. Способ изготовления армированных нитями половолоконных мембран вокруг растворимого сердечника
US20140161748A1 (en) * 2011-05-13 2014-06-12 University Of Manitoba Methods for treating sun-exposed skin
US9321014B2 (en) * 2011-12-16 2016-04-26 Bl Technologies, Inc. Hollow fiber membrane with compatible reinforcements
US9643129B2 (en) 2011-12-22 2017-05-09 Bl Technologies, Inc. Non-braided, textile-reinforced hollow fiber membrane
US9022229B2 (en) 2012-03-09 2015-05-05 General Electric Company Composite membrane with compatible support filaments
US8999454B2 (en) 2012-03-22 2015-04-07 General Electric Company Device and process for producing a reinforced hollow fibre membrane
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ.ベー. リスペリドンハプテンへの抗体及びその使用
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
PT3663317T (pt) * 2012-08-21 2023-01-23 Janssen Pharmaceutica Nv Anticorpos para haptenos de quetiapina e sua utilização
WO2014031668A2 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine and use thereof
EP3556759B1 (en) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptens of paliperidone
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CA2882557C (en) * 2012-08-21 2020-10-27 Ortho-Clinical Diagnostics, Inc. Haptens of quetiapine for use in immunoassays
AU2013305965B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Antibodies to paliperidone and use thereof
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
TR201809424T4 (tr) 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
ES2822914T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
CN104755093B (zh) 2012-08-21 2018-11-16 詹森药业有限公司 奥氮平半抗原的抗体及其用途
EP3492473B1 (en) 2012-08-21 2025-07-30 Janssen Pharmaceutica NV Haptens of olanzapine
US9227362B2 (en) 2012-08-23 2016-01-05 General Electric Company Braid welding
WO2014057439A2 (en) * 2012-10-13 2014-04-17 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
CA2908098A1 (en) * 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
CN109689598A (zh) * 2016-07-27 2019-04-26 陶氏环球技术有限责任公司 可交联的表面活性剂
WO2018045094A1 (en) * 2016-08-31 2018-03-08 The Board Of Trustees Of The Leland Stanford Junior University Ladderane lipid compounds and liposomes and methods of preparing and using the same
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
KR20250069077A (ko) * 2023-11-10 2025-05-19 아주대학교산학협력단 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064138A (en) * 1975-11-12 1977-12-20 General Mills, Inc. Amino acid derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
EP0458167B1 (en) 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
ATE169826T1 (de) 1992-01-21 1998-09-15 Macrochem Corp Iontophoretische verbesserte verabreichung von medikamenten
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US6623752B1 (en) * 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
CA2458968A1 (en) * 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs
CN100558365C (zh) 2001-09-27 2009-11-11 特拉维夫大学拉莫特有限公司 共轭的精神抑制药及其用途
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7393920B2 (en) 2003-06-23 2008-07-01 Cem Corporation Microwave-assisted peptide synthesis
WO2005002587A1 (en) 2003-07-02 2005-01-13 Astrazeneca Ab Quetiapine metabolite with antipsychotic activity
MXPA05013869A (es) 2003-07-02 2006-02-28 Astrazeneca Ab Metabolito de quetiapina.
EP1689367A1 (en) * 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
US20050171088A1 (en) 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006117675A1 (en) 2005-01-27 2006-11-09 Ocean Nutrition Canada Ltd. Fatty acid-benzenediol derivatives and methods of making and using thereof
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
WO2007092638A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
CN101636182B (zh) 2006-10-25 2013-01-16 雷蒙特亚特特拉维夫大学有限公司 具有谷氨酸nmda活性的新型精神病治疗剂
CN101616585A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
CA2785846C (en) 2009-12-31 2015-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same

Also Published As

Publication number Publication date
HRP20190057T1 (hr) 2019-03-22
SMT201900079T1 (it) 2019-02-28
CY1121106T1 (el) 2019-12-11
PL2544536T3 (pl) 2019-05-31
WO2011112657A1 (en) 2011-09-15
PT2544536T (pt) 2019-01-23
US20130045247A1 (en) 2013-02-21
US20150044261A1 (en) 2015-02-12
EP3476218A1 (en) 2019-05-01
EP2544536A1 (en) 2013-01-16
US20170246301A1 (en) 2017-08-31
TR201900067T4 (tr) 2019-02-21
EP2544536A4 (en) 2013-08-14
RS58335B1 (sr) 2019-03-29
US20170247368A1 (en) 2017-08-31
ES2705233T3 (es) 2019-03-22
US20130158007A1 (en) 2013-06-20
US9890150B2 (en) 2018-02-13
US9511149B2 (en) 2016-12-06
EP2544536B1 (en) 2018-12-12
SI2544536T1 (sl) 2019-03-29
US20170042906A1 (en) 2017-02-16
US20110223207A1 (en) 2011-09-15
US8900604B2 (en) 2014-12-02
DK2544536T3 (en) 2019-02-04
HUE042945T2 (hu) 2019-07-29
US9889198B2 (en) 2018-02-13

Similar Documents

Publication Publication Date Title
SI2544536T1 (sl) Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
EP2519101A4 (en) AMINO ACID CONJUGATES OF QUÉTIAPINE, PROCESS FOR THE PRODUCTION AND USE THEREOF
EP2521447A4 (en) FATTY FATTY ACID DERIVATIVES AND USES THEREOF
ZA201202504B (en) Process for the preparation of calcobutrol
IL222999A0 (en) Process for the preparation of pleuromutilins
GB201001345D0 (en) Process for preparing and purifying fatty acids
IL220211A0 (en) Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
IL216942A0 (en) Process for the manufacture of alkenones
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
EP2596007A4 (en) PROCESS FOR THE PREPARATION OF 17-DEOXY-CORTICOSTEROIDS
ZA201300546B (en) Process for the preparation of 3-haloalkylpyrazoles
GB0904300D0 (en) Essential fatty acid compounds
PL2398779T3 (pl) Nowy sposób wytwarzania kwasu nitroorotowego
PT2390246T (pt) Processo para a preparação de aminaftona
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
PL2598504T3 (pl) Sposób otrzymywania dimiracetamu
IL220160A (en) A process for the preparation of defrasirox
PL389568A1 (pl) Sposób otrzymywania 2-metyloglicydolu
PL391702A1 (pl) Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny
PL388933A1 (pl) Sposób otrzymywania fluorosilikonów
IL215143A0 (en) Process for the preparation of alogliptin
PL390162A1 (pl) Sposób otrzymywania kwasu akrylowego
PL390748A1 (pl) Sposób otrzymywania kwasu akrylowego